NCT00462358View on ClinicalTrials.gov

A Study of ARRY-520 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Advanced Solid Tumors
Interventions
DRUG

ARRY-520, KSP(Eg5) inhibitor; intravenous

Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.

DRUG

Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Part 1: standard of care; Part 2: standard of care.

Trial Locations (2)

21201

Marlene and Stewart Greenebaum Cancer Center, Baltimore

48201

Wayne State University, Karmanos Cancer Institute, Detroit

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00462358 - A Study of ARRY-520 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter